Literature DB >> 19774960

Arterial revascularization for upper extremity ischemia in patients with chronic kidney disease.

Jeremy A Warren1, Gautam Agarwal, James J Wynn.   

Abstract

Surgical revascularization of the upper extremity is uncommon, comprising only 4 to 18 per cent of all vascular surgical interventions. Patients with renal failure have higher rates of atherosclerotic cardiovascular and peripheral arterial disease resulting from chronic inflammation, endothelial damage associated with hemodialysis, and vascular trauma. Upper extremity arterial disease with chronic ischemia may be underrecognized in these patients. We reviewed our experience with upper extremity revascularization in patients with renal failure presenting with chronic ischemia. Four patients with longstanding chronic kidney disease developed chronic severe ischemia affecting the forearm or hand. All had previous dialysis access in the symptomatic arm, although none had a functional ipsilateral access at the time of presentation. All patients had successful revascularization with resolution of symptoms and patent bypass grafts at follow up. There was one death 4 months postoperatively and one patient has not returned for follow up. Patients with renal failure with symptomatic upper extremity arterial occlusion should be considered for revascularization of the infrabrachial arteries.

Entities:  

Mesh:

Year:  2009        PMID: 19774960

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Long-term results of ulnar and radial reconstruction with interpositional grafting using the deep inferior epigastric artery for chronic hand ischemia.

Authors:  Hee Chang Ahn; Se Won Oh; Jung Soo Yoon; Seong Oh Park
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

2.  Successful angioplasty for radial artery chronic total occlusion in a patient with digital gangrene.

Authors:  Abdurrahman Tasal; Ahmet Bacaksiz; Ercan Erdogan; Omer Goktekin
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-09-16       Impact factor: 1.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.